New Leaf Venture Partners β Full Portfolio
20 tracked investments Β· listed companies and verified rows first
iRhythm provides wearable cardiac monitoring devices and AI-powered analysis services for clinicians to diagnose heart arrhythmias.
AI & Machine LearningHealthtechMedical DevicesSan Francisco, US
Kevin M. King(Executive Officer, Director)Shelly D. Guyer(Executive Officer)William F. Willis(Executive Officer, Director)Judith Lenane(Executive Officer)Steve Johnson(Executive Officer)
BoardTiba Aynechi(Director)in
Board seatVijay LathiΒ· per SEC Form D Β· $29.5M raise Β· filed Mar 2015
Co-investorsKaiser Permanente VenturesNorwest Venture Partners
CuraSen Therapeutics is a privately funded biopharmaceutical company developing treatments that selectively activate adrenergic receptors in the brain to restore noradrenergic signaling.
BiotechHealthtech
Anthony Fordin
Co-investorsAlta PartnersLongitude Capitalabrdn plcIntermediate Capital GroupJohnson & Johnson Innovation β JJDCPappas Capital+2 more
New York, US
Michael Liang(Director)Gordon Kessler(Executive Officer)Rick Hawkins(Director)Adam Hanina(Executive Officer, Director)
Board seatVijay LathiΒ· per SEC Form D Β· $12M raise Β· filed Jul 2017
Real-time asset tracking and workflow monitoring in healthcare
San Diego, US
Brandon Hull(Director)Timothy Roche(Executive Officer, Director)Terry Linn(Director)Emily Wilson(Executive Officer)Paul Wallace(Director)Dana Mead(Director)
Board seatVijay LathiΒ· per SEC Form D Β· $1.9M raise Β· filed Aug 2017
Co-investorsIcon VenturesRex Health VenturesHERITAGE HEALTHCARE INNOVATIONKleiner PerkinsVenrock
Cleerly develops FDA-cleared, AI-driven analysis of noninvasive coronary CT (CCTA) imaging to characterize and quantify coronary artery disease.
AI & Machine LearningDigital HealthMedical DevicesDenver, US
James Min, MD(Founder)inJames K. Min(Executive Officer, Director)in
BoardLee Cooper(Director)Peter Justin Klein(Director)Scott Barclay(Director)Louis Samson(Director)
Board seatVijay LathiΒ· per SEC Form D Β· $16.8M raise Β· filed Mar 2022
Co-investorsBattery VenturesBreyer CapitalInsight PartnersLRVHealthVensana Capital
Barricaid develops a bone-anchored implant designed to reduce reherniation and reoperation in patients undergoing discectomy for large annular defects.
HealthtechMedical DevicesWoburn, US
Gregory H. Lambrecht(Director)Carey Hagan(Executive Officer, Director)Cary Hagan(Executive Officer, Director)
BoardRyan Drant(Director)inJoshua Makower(Director)
Board seatJeani DelagardelleΒ· per SEC Form D Β· $7.5M raise Β· filed Apr 2023
Co-investorsDelos CapitalNew Enterprise Associates (NEA)Questa CapitalGreenspring Associates
Bluesight provides software solutions for hospital and pharmacy operations, including inventory management, drug diversion monitoring, purchasing optimization, and compliance tools.
AI & Machine LearningEnterprise SoftwareHealthtechWashington, US
Kevin MacDonald(Executive Officer)Timothy Kress-Spatz(Executive Officer)
Board seatVijay LathiΒ· per SEC Form D Β· filed Jun 2016
Co-investorsEaston CapitalKaiser Permanente VenturesLionBirdRex Health VenturesRock Health
Kyruus Health provides a healthcare access platform that unifies provider and member data to help patients find, schedule, and access care.
Digital HealthHealthtechSaaSBoston, US
Graham Gardner(Executive Officer, Director)Julie Yoo(Executive Officer, Director)Graham Gardner, MD, MBA(Founder)in
BoardRobert Paull(Director)Robert Higgins(Director)Bryan Roberts(Director)
Board seatVijay LathiΒ· per SEC Form D
Co-investorsFrancisco PartnersTRANSFORMATION CAPITALVenrockHighland Capital PartnersLux CapitalVenrock Associates
BiotechSan Clemente, US
Richard Thompson(Executive Officer, Director)
BoardCasey Tansey(Director)David Milne(Director)John Lehmann, M.D.(Director)Kenneth Charhut(Director)
Board seatJeani DelagardelleΒ· per SEC Form D Β· $8.8M raise Β· filed Mar 2015
Co-investorsUS Venture Partners
Truveris offers a technology platform with claims analytics and PBM (pharmacy benefit manager) oversight to reduce pharmacy benefit costs through contract optimization for employers.
Data & InfrastructureDigital HealthHealthtechSaaSNew York, US
Anthony Joseph Loiacono(Executive Vice-President, Sales and Marketing)Michael Facendola(Executive Officer)Louise Shea(Chief Pharmacy Officer)inLeon Stewart Greene(Executive Vice-President, Operations)Bryan Birch(Chief Executive Officer)
BoardPhilippe Chambon(Director)
Board seatVijay LathiΒ· per SEC Form D
Co-investorsCanaan PartnersMcKesson VenturesNAV.VCTribeca Venture Partners
Abcuro develops therapies that target highly cytotoxic T cells for autoimmune diseases, including its lead candidate ulviprubart for inclusion body myositis.
BiotechHealthtechNewton, US
Steven A. Greenberg(Chief Scientific Advisor & Co-Founder)Steven A. Greenberg, MD(Chief Scientific Advisor & Co-Founder)John Alexander Martin(Executive Officer, Director)Stefano Gulla(Executive Officer)Evan Thompson(Executive Officer)David de Graaf(Executive Officer, Director)
Co-investorsBain Capital Life SciencesNew Enterprise Associates (NEA)RA CapitalSamsara BioCapitalSanofi VenturesMass General Brigham Ventures+8 more
HealthtechMenlo Park, US
Brett Hale(Executive Officer)Maria Sainz(Executive Officer, Director)
BoardLou Bock(Director)Jeani Delagardelle(Director)Casey Tansey(Director)Rodney Ferguson(Director)
Co-investorsArcher Capital GroupArcher Venture CapitalSV Health InvestorsSV Life Sciences
BiotechSan Carlos, US
Anthony P. Ford(Executive Officer, Director)Benjamin Potter(Executive Officer)Henry Skinner(Director)Liam Ratcliffe(Director)
BoardRon Hunt(Director)Loretta Tse, Ph.D.(Director)
Co-investorsAlta Partners
Cambridge, US
Annalisa Jenkins(Executive Officer, Director)
BoardBenjamin Auspitz(Director)Donald J. Hayden(Director)Allan Fox(Director)
Co-investorsF-Prime CapitalOrbiMed
HealthtechSanta Rosa, US
Dan Rose(Executive Officer)Gordon Bishop(Executive Officer, Director)David Boyle(Executive Officer)Dan T. Lemaitre(Executive Officer, Director)Chris Richardson(Executive Officer)
BoardYuval Binur(Director)
Co-investorsSV Health InvestorsFOUNDATION MEDICAL PARTNERS
Flosonics Medical makes FloPatch, a wireless wearable Doppler ultrasound device that assesses a patient's carotid arterial pulse in real time to give clinicians hemodynamic data for fluid resuscitation decisions.
Digital HealthHardwareMedical Devices
Joe Eibl(Founder)in
Co-investorsAmplify CapitalArboretum VenturesGenesys CapitaliGan PartnersRBCx
Cambridge, MA biotechnology company developing injectable synthetic biomarkers for noninvasive disease staging and treatment monitoring.
BiotechCambridge, US
Gabriel Kwong(Executive Officer)Sirshendu Roopom Banerjee(Executive Officer)
BoardTheresia Guow(Director)Amy Schulman(Director)inStan Lapidus(Director)
Co-investorsGreatPoint VenturesAcrew CapitalAspect VenturesCatalio Capital ManagementDns CapitalPolaris Partners+2 more
BiotechSouth San Francisco, US
MARTIN BABLER(Executive Officer, Director)
BoardPETER THOMPSON(Director)SRINIVAS AKKARAJU(Director)MICHAEL DYBBS(Director)inSIMEON GEORGE(Director)LEWIS J. SHUSTER(Director)
Co-investorsAccess BiotechnologyMission BiocapitalSofinnova VenturesMission Bay CapitalOrbiMedSamsara BioCapital
Qlaris Bio is a clinical-stage biotechnology company developing therapies for ophthalmology conditions.
BiotechMedical DevicesDedham, US
Thurein Htoo(Executive Officer, Director)Fred Guerard(President & Chief Executive Officer)Barbara Wirostko(Executive Officer)
BoardWende Hutton(Director)inRonald M. Hunt(Director)Andrew Danielson(Director)
Co-investorsCanaan Partnersabrdn plcCorrelation VenturesMayo Clinic Ventures
Star Therapeutics develops treatments aimed at addressing real-world patient needs.
BiotechSouth San Francisco, US
Adam Rosenthal(Founder & CEO)inNancy Stagliano(Director)Michelle Carpenter(Executive Officer)Sandip Panicker(Executive Officer)Scott Robertson(Executive Officer)Gary Patou(Executive Officer)
Co-investorsFrazier Life SciencesOrbiMedRA CapitalSanofi VenturesSofinnova VenturesAgent Capital+8 more
Rows marked βSEC filingβ are inferred from directors named on the company's SEC Form D β public regulatory data, not a portfolio list published by the firm.